INTRODUCTION
Prostate cancer (CaP) is the most frequent cancer in men in the United States, and 14% of men will be diagnosed with CaP during their lifetime [1] . There were an estimated 180,890 incident cases of CaP and 26,120 CaP deaths in the United States during 2016 [2] . CaP is a cancer that disproportionally affects Black Americans (Blacks) who are more likely to be diagnosed with and die from CaP [1] . In addition, 20-30% of men treated with radical prostatectomy and 30-50% of men treated with radiation will suffer CaP recurrence within 10 years [3] .
Previous studies have suggested that diabetes and obesity are associated with CaP recurrence [4] [5] [6] [7] [8] .
Insulin is a growth factor for CaP cells [9, 10] . Diabetics, with potentially lower circulating levels of insulin, are hypothesized to have a low-growth environment, where there is a "selection pressure" that allows only more aggressive CaP to survive [6] . Obesity, a strong risk factor for diabetes, is potentially associated with CaP aggressiveness at diagnosis and recurrence [8, 11] . Specifically, obese men are more likely to have lower testosterone levels and hyperinsulinemia, both of which have been associated with CaP aggressiveness at diagnosis and recurrence [8, [12] [13] [14] [15] [16] . CaP may also be harder to detect in obese men. Obese men can have lower Prostate-Specific Antigen (PSA) levels, larger prostates, and less accurate digital rectal exams (DRE) [8, 17] . Factors such as these can all contribute to the diagnosis of CaP at a later, more aggressive stage, which potentially increases the risk for subsequent CaP progression (persistence or recurrence).
We examined the association of diabetes and obesity with CaP progression in the Health Care Access and CaP Treatment in North Carolina (HCaP-NC) cohort, a follow-up study of North Carolina men participating in the North Carolina-Louisiana CaP Project (PCaP). Previous research on diabetes and obesity has been limited to clinically-based sample groups, and only one study examined racial differences in the association between diabetes and CaP recurrence [6] . Moreover, the two studies that examined racial differences between obesity and CaP recurrence reported inconsistent results [18, 19] .
HCaP-NC is a population-based cohort study of men with incident CaP followed for an average of 5 years after diagnosis, over-sampled for Blacks, and obtained detailed clinical, epidemiologic, and interview data, which makes it an ideal cohort to study racial differences in the association of obesity and diabetes on CaP progression.
METHODS

Study Population and Data Collection
PCaP has been described in detail [20] . PCaP is a population-based cohort of men from North Carolina and Louisiana diagnosed with histologically confirmed first diagnosis of adenocarcinoma of the prostate between July 2004 and October 2007. Eligible men were 40-79 years old at CaP diagnosis, able to complete the study interview in English, did not live in an institution (i.e., nursing home), and were not cognitively impaired at the time of the interview. Moreover, eligible men had to self-identify as African American/Black or Caucasian/White in response to the open-ended question, "What is your race?"
Research participants were visited, in-home, by a Registered Nurse. Informed consent for the interview, specimen collection, and release of tumor tissue and medical records was obtained during the in-home visit. The nurse administered a questionnaire, took biologic samples, recorded current medications, and made anthropometric measures including height and weight. Obesity was determined based on these anthropomorphic measurements. All scales were routinely calibrated and all nurses were frequently monitored to assure consistent measurement protocol adherence. The average time between CaP diagnosis and the in-home visit was 4.9 months (4.8 months in Whites and 5.0 months in Blacks). The study questionnaire included questions on comorbidities, such as diabetes, education level, and CaP screening history. Medical records abstraction gathered information on physical examinations and laboratory assays at or near diagnosis, clinical stage, Gleason grade, PSA measures, and initial CaP treatment.
North Carolina PCaP participants were invited to participate in HCaP-NC, the follow-up study, in 2009.
The follow-up cohort has been described [21] . Eight hundred and twenty-two research participants were enrolled in HCaP-NC, 366 Blacks, and 456 Whites. Research participants completed questionnaires and provided permission for medical records release annually. Medical records were requested for all men in follow-up, each year, for 3 years. In an effort to obtain comprehensive clinical data, up to three providers involved in the participant's CaP care were queried for medical records and each year providers were asked to update records from the last date of records receipt, which was included in the provider request letter. North Carolina PCaP participants were enrolled in the baseline visit between 2004 and 2007 and follow-up from 2008 to 2011, thus participants were at varying time points from diagnosis at the beginning and end of follow-up. On average, participants were followed for five years post-diagnosis. The medical records requested were specific to CaP treatments, DRE results, PSA and other laboratory results, CaP related problems, and radiology reports.
Follow-up medical records (n ¼ 822) were received for 80% of baseline PCaP research subjects from North Carolina (n ¼ 1031). Age at diagnosis was similar for participants with and without follow-up medical records available. In addition, our key exposures, diabetes (P-value for difference ¼ 0.18), and obesity (P-value for difference ¼ 0.50), were similar among participants with and without follow-up medical records. However, men without medical records were significantly more likely to have high aggressive tumors at diagnosis and somewhat more likely to have surgery than men without medical records although the difference was not significant.
Analytic Sample
HCaP-NC obtained follow-up medical records for 822 research participants. CaP progression was not determined for men if they: (i) received no treatment or only watchful waiting (n ¼ 59); (ii) received ADT as the primary treatment (n ¼ 31); (iii) underwent radical prostatectomy but no PSAs were measured within 6 months of surgery (n ¼ 33); and (iv) or information essential to determine progression status was missing, including missing treatment date, PSA values, (n ¼ 24), or other clinical factors that hampered a determination (n ¼ 3). ADT was considered the primary treatment type if the research participant received only ADT or ADT was given more than 1 year prior to radiation initiation (if ADT was received prior to radical prostatectomy, radical prostatectomy was considered the primary treatment type). Clinical factors that precluded definition of CaP progression after treatment included CaP progression at time of diagnosis and included two men with PSAs >100 at diagnosis, and a man that received chemotherapy as initial CaP treatment. Ultimately, CaP progression was determined for 672 research participants. An additional 20 men were excluded from this analysis for missing exposure or covariate information, and five underweight research participants also were excluded. The final analytic cohort consisted of 647 research participants.
Outcome, Exposure, and Covariates
The primary outcome evaluated was CaP progression. CaP progression was determined using follow-up medical records and was defined using PSA levels and treatment patterns in the follow-up period. Progression was defined as either CaP persistence after unsuccessful first course of treatment or recurrence among men for whom initial treatment was successful. Death was not included the definition of progression. For each research participant, follow-up began on date of treatment start and follow-up ended at either date of progression or date of last PSA measure
Research participants treated initially with radical prostatectomy were categorized as having a CaP progression event if the man had biochemical persistence, biochemical recurrence (BCR), or treatment failure. Persistence was defined as not achieving nadir within 6 months after surgery. Men with persistence were recorded as having CaP progression at 90 days after surgery, since radical prostatectomy typically produces nadir within 90 days. BCR was determined using the definition recommend by the American Urological Association (AUA) and was defined as a PSA !0.2 ng/ml, confirmed with a 2nd PSA !0.2 ng/ml after achieving nadir [22] . Nadir was defined as an undetectable PSA (PSA <0.1). BCR was recorded at first PSA ! 0.2 ng/ml after nadir, given that there was a second confirmatory PSA [22] . No man with BCR had a time-to-event of less than 90 days. Treatment failure was defined as secondary treatment after achieving nadir and included radiation, androgen deprivation therapy, or chemotherapy. Research participants were recorded as having a progression event on the date the secondary treatment began. All other men were considered successfully treated and were censored at end of follow-up (i.e., date of last PSA measurement available). Adjuvant radiation and adjuvant ADT were not considered secondary treatment. Radiation or ADT that was initiated 6 months after radical prostatectomy was considered adjuvant.
Research participants treated initially with radiation (either external beam radiation or brachytherapy)
were categorized as having a CaP progression event if the man had BCR or treatment failure. Men treated with radiation do not typically achieve a posttreatment nadir PSA that is undetectable, and as such persistence cannot be defined in this group. BCR was determined using the Phoenix definition and was defined as Nadir þ 2 ng/ml [23] . Nadir was defined as the lowest PSA achieved after initiation of radiation. Men with BCR were recorded as having CaP progression at the first PSA that was 2 ng/ml above nadir (Phoenix definition) [23] . Treatment failure was defined as post-radiation treatment for CaP (secondary treatment) and included radiation, ADT, or chemotherapy. Research participants were recorded as having a CaP progression event on the date the secondary treatment began. All other research participants were considered treated successfully and were censored at the end of follow-up (i.e., date of last PSA measurement available). Adjuvant ADT, defined as ADT initiated 1 year after start of radiation, was not considered a secondary treatment.
Diabetes and obesity were the primary exposure of interest. At baseline, men self-reported diabetes status during the in-home interview when asked the question, "Has a doctor or other health professional ever told you that you had diabetes or sugar diabetes?" Responses were recoded as "yes," "no," "refused," or "don't know." Obesity was determined using body mass index (BMI) and calculated based on anthropometric measurements made by the study nurse at the time of the PCaP in-home visit. Men were categorized as obese if BMI was !30 using the World Health Organization cut-point [24] . Obesity was analyzed as a dichotomous variable (obese/nonobese) as opposed to a variable with multiple categories (i.e., normal, overweight, or obese) to maximize power.
Covariates were selected based on known confounders in the literature and to maintain consistency with prior PCaP studies and included self-reported race, age at diagnosis, and education. Screening utilization and CaP aggressiveness at diagnosis were not included in our final model. Age was calculated based on age at diagnosis and coded as a continuous variable. Education was based on self-report at baseline and men were categorized as having a college degree or not. Screening history was based on selfreport and was defined having at least one PSA test or DRE prior to the PSA that led to CaP diagnosis. High CaP aggressiveness was defined both using Gleason sum alone (Gleason sum !8) and a composite measure of CaP aggressiveness that was developed for PCaP [25] . High aggressive tumors were defined as Gleason sum !8, or PSA >20 ng/ml, or Gleason sum ¼ 7 and clinical stage cT3-cT4 in the composite measure [25] .
Statistical Analysis
Progression-free survival was compared in both diabetic and nondiabetic men, and obese and nonobese men using Kaplan-Meier plots. Kaplan-Meier plots were truncated at 6 years of follow-up (average follow-up was 5 years), because only 5 patients had more than 6 years of data. However, all men, including those with greater than 6 years of follow-up (n ¼ 5), were retained in the analytical models.
The Cox Proportional Hazards model was used to assess the association of diabetes and obesity independent of diabetes with CaP progression in the primary analysis. Multivariable models were adjusted for race, age, and education. (We did not include CaP screening history in our model as greater than 94% of our cohort was screened). The proportional hazard assumption for each categorical covariate was assessed by examining the log(-log [Survival Probability]) plots. If the plots indicated a potential violation of the proportional hazards assumption, we examined whether the interaction between time and the relevant covariate was statistically significant (P-value 0.05). For continuous variables, the proportional hazard assumption was assessed using Schoenfeld Residuals. To examine racial differences, models were stratified by race. Because we had an a-priori objective to examine effect mortification across strata of race (a non-modifiable factor), and not the joint effect of race and our exposures, we did not formally test for interaction [26] . In a secondary model, we examined obesity without adjustment for diabetes using the approach described previously. All analyses were conducted using SAS 9.4 (Cary, NC).
RESULTS
Characteristics of HCaP-NC Cohort
The analytic cohort consisted of 363 Whites and 284 Blacks. The prevalence of diabetes (17.9% analytic cohort vs. 20.2% HCaP-NC), obesity (38.2% vs. 37.8%), college education (41.3% vs. 37.8%), Gleason sum !8 (8.9% vs. 10.2%), and the composite measure of high aggressive CaP (12.8% vs. 15.0%) were similar in our analytic cohort as compared to the overall HCaP-NC cohort. However, excluded Blacks were less likely to have a college education (8.6% excluded men vs. 23.6% included men) and more likely to have high aggressive CaP at diagnosis (34.2% vs. 14.4%) than Blacks included in the analytic cohort. Excluded Whites were more likely to diabetic (28.6% vs. 13.0%) and less likely to have a college education (38.7% vs. 55.1%) than Whites included in the analytic cohort.
In total, 20.9% of the cohort had a CaP progression (Table I ). BCR occurred in 11.0% of men (n ¼ 71) and treatment failure occurred in 4.1% (n ¼ 26) of men who underwent definitive treatment with radical prostatectomy or radiation. 5.9% (n ¼ 38) of men treated initially with radical prostatectomy had disease persistence. Blacks (25.0%) were more likely than Whites (17.6%) to have CaP progression.
Men who were treated successfully versus those who had CaP progression were equally likely to have diabetes as those who had CaP progression (18.0% vs. 17.8%, respectively) (Table II) . Blacks were more likely to be diabetic than Whites. Obesity was more frequent in research participants with CaP progression than those who were treated successfully. This difference was more pronounced in Whites (45.3% of Whites with CaP progression were obese compared to 30.1% of those with successful treatment) than Blacks (46.5% of Blacks with CaP progression were obese compared to 44.6% of those with successful treatment). Whites were more likely to be college educated than Blacks regardless of whether they had CaP progression or treatment success. Greater than 94% of the cohort was screened regardless of whether the man was treated successfully or had CaP progression. High aggressive CaP at diagnosis was more prevalent in men who experienced CaP progression (26.7%) than those with treatment success (9.2%). The prevalence of high aggressive CaP at diagnosis was similar in Whites (28.1%) and Blacks (25.4%) with CaP progression. The age at diagnosis was similar for those with CaP progression or treatment success.
Time to Progression
The mean progression-free survival time was 5.0 years using the Kaplan-Meier estimator of the progression-free survival probability. Kaplan-Meier plots for diabetes and obesity are presented in Figures 1  and 2 respectively. Kaplan-Meier survival estimates indicated no differences in progression-free survival for diabetics versus nondiabetics (log rank test Pvalue ¼ 0.92). However, Kaplan-Meier estimates for obesity indicated that nonobese men had a better survival probability than obese men (log rank test Pvalue ¼ 0.03). No violation of the proportional hazard assumption was found for our primary exposures or our model covariates.
Diabetes was not associated with CaP progression in the overall cohort (HR: 0.86, 95%CI: 0.54, 1.35) after adjustment for obesity, age at diagnosis, race, and college education (Table III) . Race-stratified models showed no association between diabetes and CaP progression in Whites (HR: 1.03, 95%CI: 0.50, 2.13) Research participant does not achieve nadir after radical prostatectomy. Nadir is defined as an undetectable PSA (PSA <0.1). c CaP progression is defined by primary treatment failure. Research participant received post radical prostatectomy treatment for CaP prior to meeting AUA definition for BCR (secondary treatment). d Biochemical recurrence was characterized using the Phoenix definition: Nadir þ 2 ng/ml. Nadir was defined as the lowest PSA achieved after initiation of radiation. Obesity independent of diabetes was significantly associated with CaP progression in Whites. Therefore, 
DISCUSSION
Self-reported diabetes was not associated with CaP progression among Whites or Blacks in this population-based cohort with incident CaP. Obesity was associated with CaP progression in Whites only, both with and without adjustment for diabetic status.
Consistent with this study, most previous clinic-based studies have observed no overall association between diabetes and BCR [6, 7, [27] [28] [29] [30] . However, there are some exceptions. Chan et al. reported a positive association between diabetes and BCR only among the sub-group of patients that were in a low-risk D'Amico prognostic group [7] . Whereas Patel et al. reported a positive association between diabetes and BCR in a study of diabetic men matched to men without diabetes according to their 5-year risk of recurrence as predicted by the preoperative Kattan nomogram [5, 7] .
Research examining racial differences in the association between diabetes and CaP progression is limited. Only one previous study of radical prostatectomy patients has examined racial differences in the association of diabetes and BCR [6] . Jayachandran et al., reported diabetes was significantly associated with BCR only in white, obese men from the Shared Equal-Access Regional Cancer Hospital (SEARCH) database. No association was observed in Blacks regardless of obesity status [6] . The authors suggested that race and obesity may modify the association between diabetes and BCR [6] . However, when our analysis was restricted to obese men, no association was observed between diabetes and progression in obese men overall (HR: 0.74, 95%CI: 0.40, 1.34), obese Whites (HR: 0.83, 95%CI: 0.32, 2.19) or obese Blacks (HR: 0.67, 95%CI: 0.31, 1.45).
In contrast to diabetes, most prior studies of obesity have reported a positive association with BCR [18, 19, [31] [32] [33] [34] . In our overall cohort, which had a similar number of Blacks and Whites, we observed an elevated HR for CaP progression in obese men. The positive association between obesity and progression was statistically significant only in Whites, both with and without adjustment for diabetes. Two other studies have examined racial differences in the obesity-BCR association. Jayachandran et al. reported that obesity was associated with BCR in Blacks and Whites using the SEARCH database [19] . By contrast, Spangler et al. reported that obesity was significantly associated with BCR in Blacks but not European Americans, although the HR in European Americans was elevated, in a study from the University of Pennsylvania oncology clinics [18] . Our identification of a statistically significant positive association between obesity and BCR in Whites is consistent with that observed in the SEARCH database. Both Jayachandran et al. and Spangler et al. were limited to clinic-based patients who underwent radical prostatectomy whereas this study examines a population-based cohort of racially diverse men and includes those who received radical prostatectomy or radiation [18, 19] . Another important factor to consider is model adjustment. Both Jayachandran et al. and Spangler et al. adjusted for prostate tumor characteristics in their analytic models [18, 19] . Prostate tumor characteristics were not adjusted for in our primary models because tumor characteristics mediate the primary exposures, diabetes and obesity, and CaP progression (i.e., obesity contributes to tumor aggressiveness at diagnosis which in turn promotes CaP progression). It is usually advisable that mediators not be part of the adjustment set [35] . However, we did adjust for both Gleason sum !8 and the composite measure of high aggressive CaP in sensitivity analyses, so that our results could be compared to those of others. Additional adjustment for Gleason sum !8 or the composite measure of high aggressive CaP in the multivariable model did not affect results for the association of either obesity or diabetes with CaP progression (data not shown). Moreover, because previous studies have largely been limited to a single treatment modality, in another sensitivity analysis we additionally adjusted for primary treatment type. Results were consistent with our primary models (data not shown).
Our study was limited by the use of self-reported diabetes. The sensitivity of prevalent self-reported diabetes can range from 58.5% to 70.8% and the specificity can range from 95.6% to 96.8% depending on the reference definition employed [36] . However, our estimates of diabetes prevalence in both Whites and Black 65-74 years old (18.3% and 31.3%, respectively) are consistent with recent estimates from the Behavioral Risk Factor Surveillance System (BRFSS) (20.1% and 29.6%, respectively) [37] . Moreover, we did not collect the duration of diabetes exposure, the severity of diabetes, or how well diabetes was controlled. However, when Jayachandran et al. adjusted for diabetes duration (<5 years or !5 years), the association with BCR did not significantly change [6] . Furthermore, variations in diabetes management could also have influenced our results. However, we did not have adequate power to examine the association between diabetes medication and progression.
Finally, there could be some selection bias. Selection bias occurs when the frequency of both outcome and exposure significantly differ between those excluded and included in the analysis. Men in the baseline PCaP cohort were excluded from this analysis if they did not have follow-up medical records (e.g., progression could not be determined) or if they were deceased at the time of follow-up initiation. Additionally, men who did have follow-up medical records were excluded for a variety of reasons (detailed in Analytical Sample section of Methods) predominantly because they did not have treatment.
The potential for selection bias in each instance is discussed below.
Men without medical records were significantly more likely to have high aggressive tumors at diagnosis and therefore potentially more likely to have progression than men with follow-up medical records, however, they were not more likely to have diabetes or obesity. In fact, our key exposures, obesity, and diabetes, were similarly distributed among men with and without medical records. In addition, our findings here are similar to previous finding utilizing the entire baseline PCaP cohort (i.e., men without follow-up medical records were not excluded). Previously, we found that obesity was associated with high aggressive tumors at diagnosis only in Whites and that diabetes was not associated with high aggressiveness tumors in either Whites or Blacks [38] . The consistency of our current findings with our previous analysis adds validity to our results, as the same potential for selection bias was not present in the previous analysis.
Another source of selection bias could occur with exclusion of men who were deceased, although relatively few PCaP men were deceased (n ¼ 46, 4.5%) at the time of follow-up initiation. Moreover, only 15 (1.5% of PCaP) of the deceased men had a death that was attributable to CaP. Deceased men without follow-up medical records were somewhat more likely to be diabetic (26%) than men with follow-up medical records (20%). Because deceased men may have been more likely to experience progression prior to death, it is possible our results with regards to diabetes may have been biased toward to the null. Importantly, deceased men without follow-up medical records had a similar prevalence of obesity (35%) as men with follow-up medical records (38%). Therefore, the potential for bias due to obesity status is minimized. Among men with follow-up medical records, excluded Blacks were more likely to have high aggressive CaP at diagnosis than included Blacks while excluded Whites were more likely to be diabetic than included Whites. However, most excluded men did not receive treatment or received ADT as primary treatment, therefore suggesting our analytic cohort should be representative of men treated primarily with radical prostatectomy or radiation.
There are a number of strengths in our analysis. First, we used a large, well-characterized, populationbased study of White and Black men with incident CaP, followed on average for 5 years after diagnosis. Second, this is the first study to define CaP progression in the HCaP-NC cohort, and to describe specific progression subtypes including persistence, BCR, and treatment failure among men receiving both radical prostatectomy and radiation. Finally, this populationbased study adds to the limited and inconsistent clinic-based studies of obesity, diabetes, and CaP progression among Blacks, and therefore is generalizable to a broader population.
CONCLUSIONS
Our study found that diabetes was not associated with CaP progression in the cohort as a whole, Whites, or Blacks. Obesity was associated with CaP progression in Whites, but not Blacks.
